 Merck & Co. has obtained the rights to an experimental Ebola vaccine developed by NewLink Genetics Corp., another sign of the scramble by pharmaceutical companies and other groups to find new ways to combat the deadly viral outbreak centered in West Africa.. The companies said Merck will pay NewLink $30 million upfront, plus an additional $20 million when new clinical trials to test the vaccineâ€™s efficacy get under way, which is expected by the first quarter of 2015. Merck also will pay royalties to NewLink on sales of...
  